Astrazeneca Stock Earnings Reports

AstraZeneca reported H1 2026 progress with 6% total revenue growth (11% excluding Farxiga and Brilinta generics impact) and core EPS up 11%, driven by strong demand for innovative medicines and growth across Oncology and Rare Disease. The company reiterated full-year guidance: mid- to high-single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. Pipeline and regulatory momentum remain central: 30 major market approvals in H1 including 2 new molecular entities (Etcamah, Baxfendy); positive Phase III readouts from six high-value programs in H1 (including tozorakimab in COPD, efzimfotase alfa in HPP, and sone-ve in Claudin 18.2 gastric cancer); initiation of comprehensive Phase III programs for oral GLP-1 elecoglipron (EMBOLD and ELUMINATE); and 25 key Phase III readouts planned over the next 18 months. Notable commercial developments: Oncology grew 15% (Tagrisso, Calquence, Enhertu, Imfinzi/Imjudo strong), Biopharma declined 5% (impact of loss of exclusivity for Farxiga/Brilinta), and Rare Disease grew 11% (Ultomiris, Strensiq, Koselugo momentum). CapEx rose (H1 $1.5bn; full-year ~+33% vs 2025) to support manufacturing and launches; net debt increased ~$3.5bn (dividends and deal payments). Key risks and headwinds: CARDIO‑TTRansform failed to meet its primary endpoint (Wainua), China volume‑based procurement and NRDL dynamics continue to affect growth there, ongoing working capital effects from U.S. LOE for Farxiga, and certain legal/arbitration matters (Beyfortus). Management emphasizes diversification of the portfolio, continued investment behind late‑stage assets and launch capabilities, and confidence in reaching the company’s $80bn 2030 revenue ambition (noting it is risk‑adjusted).